Hepatopancreatobiliary Carcinoma — Trials

Hepatopancreatobiliary Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

5,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,360
Recruiting: 790
Ph III recruiting: 74
Growth YoY: +10.6%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (645)

clinicaltrialsPublishedShowing 201–250 of 5,150 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06390059	EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma	completed	Phase 2	84	NovoCure Ltd.INDUSTRY	4	Sep 4, 2026	clinicaltrials
NCT06526338	Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone	recruiting	Phase 2	315	Robert C. MartinOTHER	1	Sep 4, 2026	clinicaltrials